JP2020506243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506243A5 JP2020506243A5 JP2019563650A JP2019563650A JP2020506243A5 JP 2020506243 A5 JP2020506243 A5 JP 2020506243A5 JP 2019563650 A JP2019563650 A JP 2019563650A JP 2019563650 A JP2019563650 A JP 2019563650A JP 2020506243 A5 JP2020506243 A5 JP 2020506243A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- influenza
- composition according
- virus
- naphthamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000712461 unidentified influenza virus Species 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 16
- 241000712431 Influenza A virus Species 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 241000197306 H1N1 subtype Species 0.000 claims description 4
- 241000252870 H3N2 subtype Species 0.000 claims description 4
- 241001473385 H5N1 subtype Species 0.000 claims description 4
- 241000713196 Influenza B virus Species 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 3
- WVROWPPEIMRGAB-UHFFFAOYSA-N bit225 Chemical compound C1=NN(C)C=C1C1=CC=CC2=CC(C(=O)NC(N)=N)=CC=C12 WVROWPPEIMRGAB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 241000713297 Influenza C virus Species 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 2
- 229960001084 peramivir Drugs 0.000 claims description 2
- 229960001028 zanamivir Drugs 0.000 claims description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017900385 | 2017-02-08 | ||
| AU2017900385A AU2017900385A0 (en) | 2017-02-08 | Methods of treating influenza | |
| PCT/AU2018/050085 WO2018145148A1 (en) | 2017-02-08 | 2018-02-07 | Methods of treating influenza |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506243A JP2020506243A (ja) | 2020-02-27 |
| JP2020506243A5 true JP2020506243A5 (enExample) | 2021-03-11 |
| JP7019727B2 JP7019727B2 (ja) | 2022-02-15 |
Family
ID=63106827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563650A Active JP7019727B2 (ja) | 2017-02-08 | 2018-02-07 | インフルエンザの治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10918623B2 (enExample) |
| EP (1) | EP3579833B1 (enExample) |
| JP (1) | JP7019727B2 (enExample) |
| KR (1) | KR102607599B1 (enExample) |
| CN (1) | CN110325187B (enExample) |
| AU (1) | AU2018218179B2 (enExample) |
| BR (1) | BR112019016316A2 (enExample) |
| CA (1) | CA3052503A1 (enExample) |
| ES (1) | ES2910136T3 (enExample) |
| MX (1) | MX387115B (enExample) |
| RU (1) | RU2769317C2 (enExample) |
| SG (1) | SG11201907034PA (enExample) |
| WO (1) | WO2018145148A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA34470B1 (fr) | 2010-07-22 | 2013-08-01 | Gilead Sciences Inc | Procédés et composés pour traiter des infections à virus paramyxoviridae |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| MX394858B (es) | 2015-09-16 | 2025-03-24 | Gilead Sciences Inc | Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae |
| CA3056072C (en) | 2017-03-14 | 2022-08-23 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| KR20190141747A (ko) | 2017-05-01 | 2019-12-24 | 길리애드 사이언시즈, 인코포레이티드 | (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태 |
| EP4512475A3 (en) | 2017-07-11 | 2025-05-14 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| JP7664287B2 (ja) | 2020-05-29 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | レムデシビル治療方法 |
| AU2021296841B2 (en) | 2020-06-24 | 2025-01-23 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| KR20250111239A (ko) | 2020-08-27 | 2025-07-22 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스 감염 치료를 위한 화합물 및 방법 |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| EP4346772A1 (en) | 2021-05-26 | 2024-04-10 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
| US12116380B2 (en) | 2021-08-18 | 2024-10-15 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| KR20240110039A (ko) * | 2021-11-24 | 2024-07-12 | 바이오트론 리미티드 | SARS-CoV-2 감염을 치료하는 방법 |
| KR20240154646A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| CA3244278A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| WO2023168254A1 (en) | 2022-03-03 | 2023-09-07 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| MX2024010671A (es) | 2022-03-03 | 2024-09-11 | Gilead Sciences Inc | Compuestos antivirales y metodos de elaboracion y uso de los mismos. |
| EP4536223A1 (en) | 2022-06-06 | 2025-04-16 | Gilead Sciences, Inc. | Methods for treatment of viral infections including sars-cov-2 |
| WO2024006376A1 (en) | 2022-06-29 | 2024-01-04 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US20240043466A1 (en) | 2022-06-30 | 2024-02-08 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US20240309028A1 (en) | 2023-02-16 | 2024-09-19 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| WO2025049699A1 (en) | 2023-08-31 | 2025-03-06 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| WO2025049493A1 (en) | 2023-08-31 | 2025-03-06 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| WO2025054278A1 (en) | 2023-09-06 | 2025-03-13 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| TW202517647A (zh) | 2023-09-28 | 2025-05-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122020006906B8 (pt) * | 2005-06-24 | 2021-07-27 | Biotron Ltd | compostos e composições farmacêuticas antivirais |
| ES2563477T3 (es) * | 2007-08-03 | 2016-03-15 | Biotron Limited | Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina |
| KR101369584B1 (ko) * | 2011-04-19 | 2014-03-06 | 일양약품주식회사 | 페닐-이속사졸 유도체 및 그의 제조방법 |
| MX392650B (es) * | 2014-07-07 | 2025-03-24 | Elian Llc | Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion |
| CN110870864B (zh) | 2018-08-29 | 2021-09-24 | 复旦大学 | 马来酸卡比沙明在制备抗流感病毒药物中的应用 |
-
2018
- 2018-02-07 BR BR112019016316-6A patent/BR112019016316A2/pt not_active Application Discontinuation
- 2018-02-07 CA CA3052503A patent/CA3052503A1/en active Pending
- 2018-02-07 MX MX2019009443A patent/MX387115B/es unknown
- 2018-02-07 JP JP2019563650A patent/JP7019727B2/ja active Active
- 2018-02-07 ES ES18751710T patent/ES2910136T3/es active Active
- 2018-02-07 RU RU2019126746A patent/RU2769317C2/ru active
- 2018-02-07 KR KR1020197024919A patent/KR102607599B1/ko active Active
- 2018-02-07 CN CN201880010492.9A patent/CN110325187B/zh active Active
- 2018-02-07 AU AU2018218179A patent/AU2018218179B2/en active Active
- 2018-02-07 US US16/483,958 patent/US10918623B2/en active Active
- 2018-02-07 SG SG11201907034PA patent/SG11201907034PA/en unknown
- 2018-02-07 EP EP18751710.7A patent/EP3579833B1/en active Active
- 2018-02-07 WO PCT/AU2018/050085 patent/WO2018145148A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506243A5 (enExample) | ||
| RU2019126746A (ru) | Способы лечения гриппа | |
| Liao et al. | Germacrone inhibits early stages of influenza virus infection | |
| Hayden | Antivirals for influenza: historical perspectives and lessons learned | |
| IL321503A (en) | Recombinant virus, composition comprising the same, and uses thereof | |
| Yen | Current and novel antiviral strategies for influenza infection | |
| Tarbet et al. | Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice | |
| IN2012DN01254A (enExample) | ||
| Haasbach et al. | The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus | |
| Liu et al. | A small-molecule compound has anti-influenza A virus activity by acting as a ‘‘PB2 inhibitor” | |
| HRP20130163T1 (hr) | Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba | |
| JP2014510130A5 (enExample) | ||
| Meseko et al. | Antiviral options and therapeutics against influenza: history, latest developments and future prospects | |
| Govorkova et al. | Therapeutics against influenza | |
| Kumar et al. | Oseltamivir analogs with potent anti-influenza virus activity | |
| Kiselev et al. | A new antiviral drug Triazavirin: results of phase II clinical trial | |
| US20140121237A1 (en) | Methods for Inhibiting Virus Replication | |
| Tian et al. | Dihydromyricetin is a new inhibitor of influenza polymerase PB2 subunit and influenza-induced inflammation | |
| Yang et al. | Influenza virus entry inhibitors | |
| Li et al. | Cilnidipine exerts antiviral effects in vitro and in vivo by inhibiting the internalization and fusion of influenza A virus | |
| JP2010528053A5 (enExample) | ||
| Leyva-Grado et al. | Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses | |
| WO2017201030A1 (en) | Methods of treating viral infection | |
| Park et al. | Antiviral agents against influenza viruses | |
| NZ755900B2 (en) | Methods of treating influenza |